SEMA4B, His, Human
SEMA4B, His, Human

The purity of SEMA4B, His, Human is greater than 95% as determined by SEC-HPLC.

SEMA4B, His, Human

SEMA4B, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEMA4B, His, Human

Semaphorin 4B (SEMA4B) inhibits the invasion of non-small cell lung cancer (NSCLC) through PI3K-dependent suppression of MMP9 activation. SEMA4B may induce FoxO1 nuclear retention through suppressing PI3K/Akt signaling pathway, which subsequently inhibited cell growth through the direct nuclear target of FoxO1, p21. A role of SEMA4B in suppressing NSCLC growth, besides its role in inhibiting cell metastasis, and highlights SEMA4B as a promising therapeutic target for NSCLC.
Z05802
¥59,694.00

Ask us a question
Product Introduction
Species Human
Protein Construction
SEMA4B (Leu44-Glu717)_x000D_
Accession # Q9NPR2		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 75.8 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 80-110 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • SEMA4B, His, Human
    • SEMA4B, His, Human

    The purity of SEMA4B, His, Human is greater than 95% as determined by SEC-HPLC.

  • SEMA4B, His, Human
    • SEMA4B, His, Human

    SEMA4B, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Semaphorin 4B (SEMA4B) inhibits the invasion of non-small cell lung cancer (NSCLC) through PI3K-dependent suppression of MMP9 activation. SEMA4B may induce FoxO1 nuclear retention through suppressing PI3K/Akt signaling pathway, which subsequently inhibited cell growth through the direct nuclear target of FoxO1, p21. A role of SEMA4B in suppressing NSCLC growth, besides its role in inhibiting cell metastasis, and highlights SEMA4B as a promising therapeutic target for NSCLC.
Synonyms Semaphorin-4B; Semaphorin-C; SEMA4B; KIAA1745; SEMAC; MGC131831; SemC

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.